Transplant Surgery »  Meet the Team »  Hepatology »  Neil Mehta, M.D.
Neil Mehta, M.D.

Neil Mehta, M.D.

Assistant Professor of Medicine
General Hepatology and Liver Transplantation
Department of Medicine

Contact Information

Academic Office
Division of Gastroenterology
513 Parnassus Avenue, Room S-357     
San Francisco, CA 94143-0358
(415) 476-6422 - Phone
(415) 476-0659 - Fax
Open Popup
  • Johns Hopkins University, BA, Neuroscience, 1998-2002
  • University of California, San Francisco School of Medicine, MD, 2002-2006
  • Hospital of the University of Pennsylvania, Intern, Internal Medicine, 2006-2007
  • Hospital of the University of Pennsylvania, Resident, Internal Medicine, 2007-2009
  • University of California, San Francisco, Fellow, Gastroenterology, 2009-2012
  • University of California, San Francisco, Fellow, Transplant Hepatology, 2012-2013
  • American Board of Internal Medicine
  • American Board of Internal Medicine - Gastroenterology
  • American Board of Internal Medicine - Transplant Hepatology
  • UCSF Liver Center
  • Cardiopulmonary complications of chronic liver disease
  • Hepatocellular carcinoma (HCC)
  • Liver injury and repair (Liver transplantation)
  • Liver transplantation outcomes including expanded criteria liver transplants

Dr. Neil Mehta is a general and transplant hepatologist, specializing in treating patients with hepatocellular carcinoma (HCC) and those with end-stage liver disease needing liver transplantation.

After earning his undergraduate degree from Johns Hopkins University and MD degree from UCSF, he completed residency at the Hospital of the University of Pennsylvania and both gastroenterology and advanced/transplant hepatology fellowships at UCSF. Dr. Mehta is a member of the American Association for the Study of Liver Diseases and board-certified by the American Board of Internal Medicine in Internal medicine, Gastroenterology, and Transplant Hepatology.

Dr. Mehta is engaged in research investigating clinical outcomes in patients with end-stage liver disease. His research focuses on two main areas:

  • Understanding issues related to the diagnosis and management of patients with hepatocellular carcinoma (HCC) particularly with regards to outcomes in liver transplantation. Specific topics we are currently interested in are evaluating the risk of HCC recurrence post-transplant based on transplant waiting times, creating an HCC recurrence risk score, and downstaging tumors in to conventional transplant criteria.
  • Understanding the role of iron overload in patients listed for liver transplant, specifically with regards to both hepatic and cardiac iron deposition.

Mr. Mehta is also conducting research related to the diagnosis and management of patients with hepatocellular carcinoma (HCC) particularly with regards to outcomes in liver transplantation.This includes a multicenter project with CPMC and Scripps to understand the role of downstaging tumors into conventional transplant criteria. He is also pursuing projects to address the risk of HCC recurrence post-transplant based on transplant waiting times as well as to create an HCC recurrence risk score. These projects are being done collaboratively with the Mayo clinic in Rochester and Jacksonville.

Dr. Mehta is also pursuing research to help optimize the management of iron overload in patients listed for liver transplant, specifically with regards to both hepatic and cardiac iron deposition.

Most recent publications from a total of 29
  1. Sadler EM, Mehta N, Bhat M, Ghanekar A, Greig PD, Grant DR, Yao F, Sapisochin G. Liver transplantation for NASH-related hepatocellular carcinoma versus non-NASH etiologies of hepatocellular carcinoma. Transplantation. 2018 Jan 10. View in PubMed
  2. Mehta N, Guy J, Frenette CT, Dodge JL, Osorio RW, Minteer WB, Roberts JP, Yao FY. Excellent Outcomes of Liver Transplantation Following Down Staging of Hepatocellular Carcinoma to Within Milan Criteria-a Multi-Center Study. Clin Gastroenterol Hepatol. 2017 Nov 23. View in PubMed
  3. Mehta N, Dodge JL, Roberts JP, Yao FY. Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database. Am J Transplant. 2017 Oct 25. View in PubMed
  4. Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY. Misdiagnosis of Hepatocellular Carcinoma in Patients Receiving no Loco-regional Therapy Prior to Liver Transplant: An Analysis of the OPTN Explant Pathology Form. Clin Transplant. 2017 Sep 07. View in PubMed
  5. Mehta N, Heimbach J, Lee D, Dodge JL, Harnois D, Burns J, Sanchez W, Roberts JP, Yao FY. Wait Time of Less Than 6 and Greater Than 18 Months Predicts Hepatocellular Carcinoma Recurrence After Liver Transplantation: Proposing a Wait Time "Sweet Spot". Transplantation. 2017 Sep; 101(9):2071-2078. View in PubMed
  6. Lewin SM, Mehta N, Kelley RK, Roberts JP, Yao FY, Brandman D. Liver transplantation recipients with nonalcoholic steatohepatitis have lower risk hepatocellular carcinoma. Liver Transpl. 2017 Aug; 23(8):1015-1022. View in PubMed
  7. Sabatino JJ, Mehta NJ, Kakar S, Zamvil SS, Cree BAC. Acute liver injury in a Glatopa-treated patient with MS. Neurol Neuroimmunol Neuroinflamm. 2017 Jul; 4(4):e368. View in PubMed
  8. Mehta N, Heimbach J, Harnois DM, Sapisochin G, Dodge JL, Lee D, Burns JM, Sanchez W, Greig PD, Grant DR, Roberts JP, Yao FY. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant. JAMA Oncol. 2017 Apr 01; 3(4):493-500. View in PubMed
  9. Mehta NJ, Celik AD, Peters MG. Screening for hepatocellular carcinoma: What is missing? Hepatol Commun. 2017 Feb; 1(1):18-22. View in PubMed
  10. Mehta N, Yao FY. Transarterial Radioembolization for Hepatocellular Carcinoma: Who, When… and Y(90)? Gastroenterology. 2016 Dec; 151(6):1062-1065. View in PubMed
  11. View All Publications
Publications provided by UCSF Profiles, powered by CTSI at UCSF. View profile of Neil Mehta, M.D.
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.

X